Millipore Sigma Vibrant Logo

475838 Mifepristone - CAS 84371-65-3 - Calbiochem

View Products on Sigmaaldrich.com
475838
가격 및 재고 조회

개요

Replacement Information

주요 사양표

CAS #Empirical Formula
84371-65-3C₂₉H₃₅NO₂

가격 및 재고여부

카탈로그 번호 재고 정보패킹 포장 단위 가격(VAT 별도) 수량
475838-50MGCN
재고 정보 검색...
현재 재고 없음
현재 재고 없음
예상 출고 가능일 
단종품
제한된 수량 가능
재고여부 확인
    Remaining: will advise
      Remaining: will advise
      추천사항
      고객 서비스로 문의
      Contact Customer Service

      Plastic ampoule 50 mg
      가격 검색...
      가격을 검색할 수 없습니다
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      가격 문의 추가 정보
      ()이 할인됨
       
      가격 문의
      Description
      OverviewA cell-permeable synthetic steroid that acts as a potent antagonist of progesterone and glucocorticoid receptors. Inhibits P-glycoprotein (P-gp) function and down-modulates P-gp mediated drug resistance. Displays anti-angiogenic effects and suppresses vascular endothelial growth factor (VEGF) production. Regulates the expression of Fas and FasL in mouse endometrium and TRAIL in prostate cancer cells. As an antioxidant, it offers neuroprotection against controlled cortical impact (CCI) in CA1 pyramidal cells, as well as Aβ-, H2O2-, and glutamate-induced injury to mouse hippocampal HT22 cells.
      Catalogue Number475838
      Brand Family Calbiochem®
      Synonyms(11β,17β)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one, RU-486
      References
      ReferencesMcCullers, D.L., et al. 2002. Neuroscience 109, 219.
      Sidell, N., et al. 2002. Ann. N. Y. Acad. Sci. 955, 159.
      Gao, F., et al. 2001. Acta Pharmacol. Sin. 22, 524.
      Hyder, S.M., et al. 2001. Int. J. Cancer 92, 469.
      Lam, F.C., et al. 2001. J. Neurochem. 76, 1121.
      Sridhar, S., et al. 2001. Cancer Res. 61, 7179.
      Behl, C., et al. 1997. Eur. J. Neurosci. 9, 912.
      Greb, R.R., et al. 1997. Hum. Reprod. 12, 1280.
      Gruol, D.J., et al. 1994. Cancer Res. 54, 3088.
      Product Information
      CAS number84371-65-3
      ATP CompetitiveN
      FormYellow solid
      Hill FormulaC₂₉H₃₅NO₂
      Chemical formulaC₂₉H₃₅NO₂
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetProgesterone and glucocorticoid receptors
      Purity≥99% by titration
      Physicochemical Information
      Cell permeableY
      ContaminantsSteroid substances: ≤0.1%
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSKG2955000
      Safety Information
      R PhraseR: 60-61

      May impair fertility.
      May cause harm to the unborn child.
      S PhraseS: 22-36/37/39-45

      Do not breathe dust.
      Wear suitable protective clothing, gloves and eye/face protection.
      In case of accident or if you feel unwell, seek medical advice immediately (show the label where possible).
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Carcinogenic / Teratogenic
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      카탈로그 번호 GTIN
      475838-50MGCN 04055977184976

      Documentation

      Mifepristone - CAS 84371-65-3 - Calbiochem MSDS

      타이틀

      물질안전보건자료(MSDS) 

      Mifepristone - CAS 84371-65-3 - Calbiochem Certificates of Analysis

      TitleLot Number
      475838

      References

      참고문헌 보기
      McCullers, D.L., et al. 2002. Neuroscience 109, 219.
      Sidell, N., et al. 2002. Ann. N. Y. Acad. Sci. 955, 159.
      Gao, F., et al. 2001. Acta Pharmacol. Sin. 22, 524.
      Hyder, S.M., et al. 2001. Int. J. Cancer 92, 469.
      Lam, F.C., et al. 2001. J. Neurochem. 76, 1121.
      Sridhar, S., et al. 2001. Cancer Res. 61, 7179.
      Behl, C., et al. 1997. Eur. J. Neurosci. 9, 912.
      Greb, R.R., et al. 1997. Hum. Reprod. 12, 1280.
      Gruol, D.J., et al. 1994. Cancer Res. 54, 3088.

      Brochure

      Title
      Alzheimer's Disease Brochure & Technical Guide
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision28-April-2009 RFH
      Synonyms(11β,17β)-11-(4-(Dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one, RU-486
      DescriptionA cell-permeable, synthetic steroid that acts as a potent antagonist of progesterone and glucocorticoid receptors. Reported to inhibit P-glycoprotein (P-gp) function and down-modulate P-gp mediated drug resistance. Also displays anti-angiogenic effects and suppresses vascular endothelial growth factor (VEGF) production. Shown to regulate the expression of Fas and FasL in mouse endometrium and of TRAIL in prostate cancer cells. As an antioxidant, it is reported to offer neuroprotection against controlled cortical impact (CCI) in CA1 pyramidal cells, as well as Aβ-, H2O2-, and glutamate-induced injury to mouse hippocampal HT22 cells.
      FormYellow solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number84371-65-3
      RTECSKG2955000
      Chemical formulaC₂₉H₃₅NO₂
      Structure formulaStructure formula
      Purity≥99% by titration
      ContaminantsSteroid substances: ≤0.1%
      SolubilityEthanol (10 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Carcinogenic / Teratogenic
      Merck USA index14, 6186
      ReferencesMcCullers, D.L., et al. 2002. Neuroscience 109, 219.
      Sidell, N., et al. 2002. Ann. N. Y. Acad. Sci. 955, 159.
      Gao, F., et al. 2001. Acta Pharmacol. Sin. 22, 524.
      Hyder, S.M., et al. 2001. Int. J. Cancer 92, 469.
      Lam, F.C., et al. 2001. J. Neurochem. 76, 1121.
      Sridhar, S., et al. 2001. Cancer Res. 61, 7179.
      Behl, C., et al. 1997. Eur. J. Neurosci. 9, 912.
      Greb, R.R., et al. 1997. Hum. Reprod. 12, 1280.
      Gruol, D.J., et al. 1994. Cancer Res. 54, 3088.